Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The lancet …, 2016 - thelancet.com
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The Lancet …, 2016 - elibrary.ru
The study was funded by the sponsor and designed by the principal investigators (GG and
TM) and the sponsor. The sponsor was responsible for data collection, data analysis, and …
TM) and the sponsor. The sponsor was responsible for data collection, data analysis, and …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The Lancet …, 2016 - infona.pl
Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor
selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met …
selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd… - The Lancet …, 2016 - snucm.elsevierpure.com
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The Lancet …, 2016 - Elsevier
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
[PDF][PDF] Osimertinib for pretreated EGFRThr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova, JS Lee… - 2016 - academia.edu
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The Lancet …, 2016 - europepmc.org
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd… - The Lancet …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd… - The Lancet …, 2016 - cuk.elsevierpure.com
Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR …
[引用][C] Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
G Goss, CM Tsai, FA Shepherd, L Bazhenova… - The Lancet …, 2016 - cir.nii.ac.jp
Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2):
a multicentre, open-label, single-arm, phase 2 study | CiNii Research CiNii 国立情報学研究所 …
a multicentre, open-label, single-arm, phase 2 study | CiNii Research CiNii 国立情報学研究所 …